Connect Biopharma (CNTB) vs Grace Therapeutics (GRCE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Grace Therapeutics (GRCE) has outperformed Connect Biopharma (CNTB) over the past year, losing 46.4% versus a loss of 80.6%. Over five years, GRCE leads with a -79.3% price change compared with -86.9% for CNTB. Connect Biopharma is the larger company by market cap ($38.0 million vs $36.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CNTB | GRCE |
|---|---|---|
| Share price | $0.59 | $1.71 |
| Market cap | $38.05M | $35.97M |
| 1-day change | -6.08% | -0.58% |
| YTD return | -79.08% | -50.58% |
| 1-year return | -80.59% | -46.39% |
| 5-year return | -86.89% | -79.35% |
| EPS (TTM) | $-1.14 | $-1.16 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $64.00K | — |
| Revenue growth (YoY) | -99.75% | — |
| Net income (latest FY) | $-55.48M | $-7.79M |
| Operating margin | -90740.63% | — |
| Net margin | -86687.50% | — |
| 52-week high | $3.82 | $5.18 |
| 52-week low | $0.55 | $1.64 |
| Distance from 52-week high | -84.55% | -66.99% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +896.61% | +243.27% |
| Average volume | 3.98M | 119.27K |
| Shares outstanding | 64.49M | 21.04M |
| Employees | 64 | 5 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- GRCE has outperformed CNTB by 34.2 percentage points over the past year.
About Connect Biopharma
CNTB stock →Connect Biopharma Holdings Limited operates as a clinical-stage biopharmaceutical company in the United States. It develops rademikibart, a human monoclonal IgG4 antibody directed against IL-4Ra in two Phase 2 trials for the treatment of acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD).
Health Care · Biotechnology: Pharmaceutical Preparations · 64 employees
About Grace Therapeutics
GRCE stock →Grace Therapeutics, Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 5 employees
CNTB vs GRCE FAQ
Which is bigger, Connect Biopharma or Grace Therapeutics?
Connect Biopharma (CNTB) is larger, with a market capitalization of $38.05M compared with $35.97M for Grace Therapeutics (GRCE).
Which stock has performed better over the past year, CNTB or GRCE?
GRCE returned -46.39% over the past 12 months, compared with -80.59% for CNTB (price return, excluding dividends). Past performance does not predict future results.
Are Connect Biopharma and Grace Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.